
Humira Biosimilars Gain Ground as Doctors Adjust And New Therapies Rise
Immunology physicians are starting to adjust to the new treatment paradigm brought on by the entry of Humira biosimilars, sending sales of AbbVie’s mega-blockbuster down precipitously. But the transition has been slow, with these emerging competitors …